CBPO [China Biologic Products] 10-Q:

[] [STATE OF DELAWARE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINA BIOLOGIC PRODUCTS, INC. Corporation China Biologic Products, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ The name of the Corporation is China Biologic Products, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State] [Settlement Agreement This settlement agreement (this “Agreement”) was entered into by and among the following parties (the “Parties,” and each a “Party”) in Yunyan District, Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. Party B: Guiyang Dalin Biologic Technologies Co., Ltd. Party C: Guizhou Jie’an Company Party D: Shenzhen Yigong Shengda Technology Co.,] [Guarantee Agreement This Guarantee Agreement (this “Agreement”) was entered into by the following parties (the “Parties,” and each a “Party”) at No.808 Meeting Room No. 3 Office Building of Guizhou Province Government in Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. (“Guizhou Taibang”) Party B: Guiyang Dalin Biologic Technologies Co., Ltd. (“Guiyang Dalin”)] [CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of this July 1, 2016 (the “Effective Date”) by and between CHINA BIOLOGIC PRODUCTS, INC., a Delaware corporation (the “Company”) and Mr. Hui (David) Li (hereinafter referred to as the “Consultant”). WHEREAS, NOW, THEREFORE, Senior Strategic and Investment Consulting Agreement 1. provided however Term 2. Compensation 3. (c) Consultant] [Second Amended and Restated Employment Agreement Agreement Company Executive This Second Amended and Restated Employment Agreement (this “ 2012 Agreement WHEREAS, the Company and the Executive entered into an employment agreement dated as of May 11, 2012 (the “ 2014 Agreement WHEREAS, the Company and the Executive entered into a renewal employment agreement dated as of May 11, 2014 (the] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer) Chief Financial Officer]

CBPO [China Biologic Products] SC 13G: (Original Filing)

[1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research Global Investors ** 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 3,031,654 6 SHARED VOTING POWER NUMBER OF SHARES NONE BENEFICIALL Y OWNED]

CBPO [China Biologic Products] 8-K: (Original Filing)

[China Biologic Opens Plasma Collection Station in Hebei Province BEIJING, China – June 20, 2016 – The Company received approval to build two new plasma collection stations in Xinglong and Daming Counties, respectively, in October 2014. The new Xinglong station covers a collection territory of approximately 0.4 million people. The Company expects the new station to reach its designed annual] []

CBPO [China Biologic Products] 8-K: China Biologic Opens Plasma Collection Station in Hebei

[China Biologic Opens Plasma Collection Station in Hebei Province BEIJING, China – June 20, 2016 – The Company received approval to build two new plasma collection stations in Xinglong and Daming Counties, respectively, in October 2014. The new Xinglong station covers a collection territory of approximately 0.4 million people. The Company expects the new station to reach its designed annual] []

CBPO [China Biologic Products] SC 13D/A: CUSIP No. 16938C106 1. Names of reporting persons.

[CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

CBPO [China Biologic Products] 424B7: 7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June

[7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June 2, 2016 (To Prospectus dated June 5, 2015) 2,775,000 Shares China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 2,775,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]

CBPO [China Biologic Products] 8-K: (Original Filing)

[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [June 6, 2016 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Shares Selling Stockholders Underwriting Agreement We understand that 2,775,000 shares of Common Stock (the “ As legal counsel to] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – June 2, 2016 The shares to be sold in this offering represent approximately 10.4 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] []

Skip to toolbar